The present study was
Antithyroid drugs (ATD) have been widely used for the management of hyperthyroidism due to Graves' disease. Propylthiouracil (PTU) and methimazole (MMI) are ATD commonly used throughout the world. Usually 30-60mg MMI or 300-600 mg PTU per day is recommended as the initial dose of ATD, and the average dose required to maintain the euthyroid state is 5-20mg MMI or 50-200mg PTU per day (Solomon 1986 , DeGroot et al., 1984 . There has so far been no useful indicator with which to determine the timing of the reduction of the initial dose of ATD, which has been done empirically after fixed periods or after the achievement of the euthyroid state (DeGroot et al., 1984 , Solomon 1986 , Glinoer et al., 1987 , Larsen 1988 , Nagayama et al., 1989 , Solomon et al., 1990 . The recent development of supersensitive assays for serum TSH concentration has made it possible to examine the pituitary-thyroid axis in detail (Barger et al., 1985 , Caldwell et al., 1985 , Cobb et al., 1984 , Keer et al., 1984 , Seth et al., 1984 . However, the usefulness of a supersensitive TSH assay in monitoring the dose of ATD in the treatment of hyperthyroidism has not yet been sufficiently investigated (Jaffiol et al., 1987) . The purpose of the present study is, therefore, to evaluate whether or not the normalization of serum TSH levels in a supersensitive assay, during the initial treatment with ATD, is a useful indicator for determining the timing of the reduction of the initial dose of ATD in patients with Graves' disease. 
Subjects and Methods

Patients
Results
Fifty patients with Graves' disease were divided into four groups (MMI-1, MMI-2, PTU-1 and PTU-2) as follows. Twentynine of 50 patients were treated with MMI and the remaining 21 with PTU. The initial dose of ATD was maintained until the achievement of the euthyroid state (normalization of serum free T3 and free T4 levels), and then was reduced either before the serum TSH level was in the normal range in 9 of 29 patients treated with MMI (group MMI-1) and 8 of 21 Vol.37, No.6 ANTITHYROID DRUGS IN GRAVES' DISEASE patients treated with PTU (group PTU-1), or after the serum TSH level was in or above the normal range in 20 of 29 patients treated with MMI (group MMI-2) and 13 of 21 patients treated with PTU (group PTU-2). Blood samples for the measurements of serum TSH levels described above were taken on the day when the initial dose of ATD was reduced, so that the inverval between the blood sampling and the evaluation of the data (1-4 weeks in the present study) was not considered for the group division. However, there was, in practice, a time lag between the normalization of serum thyroid hormone levels and the reduction of the initial dose of ATD in groups MMI-1 and PTU-1, and between the normalization of serum TSH levels and the reduction of the initial dose of ATD in groups MMI-2 and PTU-2 (see below). The clinical and laboratory data for the four groups are summarized in Table 1 . There were no significant differences among the four groups in sex, age, initial serum free T3 or free T4 levels, prevalence of MCHA, TGHA or TBIAb, 24h-thyroid 123I uptake values, goiter size or the duration of the disease.
The clinical courses of patients in the four groups are summarized in Table 2 . There were no significant differences between groups MMI-1 and MMI-2 and groups PTU-1 and PTU-2 in the initial and modified doses of ATD. These doses of ATD were nearly the same as those being used throughout Japan (Nagayama et al., 1989) . The euthyroid state was obtained after approximately 6 weeks of therapy in all groups. Then the initial dose of ATD was reduced after approximately 10 weeks of therapy in groups MMI-1 and PTU-1 (This time lag of 4 weeks represents the interval between the blood sampling and the evaluation of the data). On the other hand, serum TSH increased to detectable levels after approximately 14 weeks of therapy and then the initial dose of ATD was reduced after approximately 17 weeks of therapy in groups MMI-2 and Table1. Clinical and laboratory data on patients with hyperthyroidism due to Graves' disease before ATD treatment.
Groups MMI-1 and PTU-1 consisted of patients in whom the initial dose of MMI and PTU, respectively, was reduced after serum levels of T4 or T3 were restored to the normal range; Groups MMI-2 and PTU-2 consisted of those in whom each was reduced after the serum TSH level was in/above the normal range. MCHA, thyroid microsomal antigen autoantibodies; TGHA, thyroglobulin autoantibodies. The number of subjects is in parenthesis. There are no significant differences among the four groups. PTU-2 (This time lag of 3 weeks also represents the abovementioned interval). Thus, the mean durations of the administration of the initial dose of ATD in groups MMI-2 and PTU-2 were significantly longer than those in groups MMI-1 and PTU-1, respectively (P<0.01). As a result, 4 patients (44.4%) in group MMI-1, 20 (100%) in MMI-2, 2 (25%) in PTU-1 and 7 (53.8%) in PTU-2 developed low serum free T4 levels, and also 1(11%) in MMI-1 15 (75%) in MMI-2 and 3 (23.1%) in PTU-2 developed low free T3 levels. Furthermore, serum TSH levels increased to over the normal range after approximately 15 weeks of therapy in 3 (33%) of MMI-1, 18(90%) of MMI-2 and 5 (38.5%) of PTU-2. Serum free T3 levels of all patients in group PTU-1 remained normal. The incidences of low free thyroid hormone and increased TSH in group MMI-2 were significantly higher than those in all other groups (P<0.01), and the incidence of TSH increase in group PTU-2 was significantly higher than that 
Discussion
In the present study, we demonstrated that the continuous administration of the initial dose of ATD (particularly MMI) until the period 3 to 4 weeks after the normalization of the serum TSH levels causes a high incidence of the hypothyroid Our and previous reports (Harada et al., 1975 , Haug et al., 1977 , Fisher et al., 1982 show as that with MMI in the present study.
The reason for this difference is unclear. ATD has been found to have immunosuppressive effects (Wall et al., 1976 , McGregor et al., 1980 , Bliddal et al., 1982 , Kasagi et al., 1986 , Mashimo et al., 1988 . Tamai et al.(1987) and Wenzel et al.(1984) reported Graves' patients who had developed hypothyroidism during ATD treatment probably due to the appearance of antibodies that block TSH stimulation. Although we did not measure thyroid stimulating antibody (TSAb) and TBIAb values during ATD treatment in the present study, serum TSAb and TBIAb values after approximately 15 weeks of ATD treatment are still definitely high (Bliddal et al., 1982 , Wenzel et al., 1984 , Kasagi et al., 1986 , Mashimo et al., 1988 . It is, therefore, very unlikely that the development of hypothyroidism in the present study results from the appearance of blocking-type TSH receptor antibody.
The data from surveys of the management of hyperthyroid Graves' disease (Glinoer et al.,1987 , Nagayama et al., 1989 , Solomon et al., 1990 show that in Japan the initial dose of ATD is reduced mainly according to thyroid function, but after Japan, of those who reduce the initial dose of ATD according to thyroid function, 10% reduce it after basal TSH levels increase to measurable levels in a supersensitive assay and 4% continue it until thyroid hormone levels fall below the normal range.
TSH increase can cause further thyroid enlargement, probably an exacerbation of eye symptoms and sometimes a"rollercoaster" course of hyper-and hypothyroid states (Solomon 1986 ). Indeed, Shi et al. (1985) reported that 23/30 (77%) of hypothyroid Graves' patients with MMI had symptoms and/or signs of hypothyroidism. Although it is at present unclear whether the overdose of ATD affects the long-term prognosis in patients with Graves' disease, our data suggest that the initial dose of Endocrinol. Japon. December 1990 ATD (particularly MMI) should be reduced before serum TSH levels increase to the normal range, or alternatively, adjunctive therapy with thyroid hormone should be considered. 
